GPX4, ACSL4, P53, and FTH1 are currently recognized as biomarkers of ferroptosis in gliomas (Li et al., 2020; Yang et al., 2014); however, they are not considered the gold standard, and further auxiliary studies are necessary to validate their efficacy. This evidence concerns the gene TP53 and central nervous system cancer.